1 (905) 580-2802 info@madhattr.ca
  • Facebook
  • Twitter
  • Facebook
  • Twitter
  • English
    • French
Hereditary Amyloidosis Canada
  • Home
  • About
  • Email Your Elected Representative
  • Meet Your Elected Representative
  • Latest Updates
  • Advocate Now!
Select Page

Pan-Canadian Pricing Negotiations Successfully Completed for Tegsedi™ (inotersen)

May 25, 2020 | Uncategorised

Hereditary Amyloidosis Canada (HAC) is pleased to learn that Akcea Therapeutics and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully completed negotiations for Tegsedi™ (inotersen) by signing a Letter of Intent (LOI) on April 30, 2020. Tegsedi is...

HAC launches #stophATTRnow campaign to advocate for publicly funded access to new treatments

Feb 26, 2020 | Uncategorised

One year ago, we launched Hereditary Amyloidosis Canada (HAC) because we saw a need for a dedicated community, support group and information and resources for people living with hATTR amyloidosis. Since then, much has changed in the way hATTR amyloidosis is managed in...
© 2020 Hereditary Amyloidosis Canada | Privacy Policy

The information provided on this website is not intended to replace the medical advice of your doctor or healthcare provider. Please consult your healthcare provider for advice about your individual medical condition.

Hereditary Amyloidosis Canada requests grants from individuals and organizations to support its programs and activities to benefit the lives of Canadian hATTR amyloidosis patients, their families and caregivers, and allocates those funds free from influence.